GlassScriptPhysician profile
Sarah K Broadhead
NPI 1851507933
$1,911.81
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $160 · 2021: $197 · 2022: $297 · 2023: $324 · 2024: $431 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $683.28 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $243.02 | 2019-2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $162.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $128.89 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $96.60 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.98 | 2019-2020 | |
| Neos Therapeutics, LP | $77.79 | 2020-2023 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $50.74 | 2019 | |
| Kaleo, INC. | $47.05 | 2021-2023 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $46.65 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.50 | 2022-2023 | Flumist Quadrivalent |
| Corium, LLC | $38.51 | 2022-2024 | Azstarys |
| Ultragenyx Pharmaceutical INC. | $34.98 | 2021-2023 | |
| Sobi, INC | $32.65 | 2019-2021 | |
| Alk-Abello, INC | $28.71 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $19.36 | 2025 | Jornay Pm |
| Philips North America LLC | $18.20 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $15.78 | 2025 | Neffy |
| Kyowa Kirin, INC. | $14.50 | 2025 | |
| Adlon Therapeutics L.P. | $12.63 | 2021 | |
| Shire North American Group INC | $11.82 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.80 | 2019 | |
| Glaxosmithkline, LLC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Broadhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.